Differences in Lipid Measurements by Antiretroviral Regimen Exposure in Cohorts from Asia and Australia
Table 1
Patient characteristics at study entry.
Characteristics
AHOD,
TAHOD,
*
Age (years)
Mean ± SD
<0.001
Gender
Male
<0.001
Female
Transgender***
HIV exposure category
Homosexual contact ± IDU
618 (78.4)
485 (23.7)
<0.001
IDU ± heterosexual
25 (3.2)
45 (2.2)
Heterosexual
65 (8.2)
1,341 (65.6)
Other
80 (10.2)
174 (8.5)
Missing
06 (0.7)
08 (0.4)
HBV coinfection
Negative
649 (81.8)
1,376 (67)
<0.001
Positive
22 (2.8)
171 (8.3)
Missing/never tested
123 (15.5)
506 (24.6)
HCV coinfection
Negative
631 (79.5)
1,365 (66.5)
<0.001
Positive
87 (11)
128 (6.2)
Missing/never tested
76 (10)
560 (27.3)
HIV RNA < 500 copies/mL
326 (41)
372 (18)
<0.001
Missing
58 (7.3)
880 (43)
CD4+ count cells/μL
360 (219–569)
161 (50–280)
<0.001**
Median (IQR)
Missing
58 (7.3)
264 (12.9)
Cumulative exposure to cART in years
Median (IQR)
2 (0–8.2)
0 (0–0.2)
<0.001**
Number ART naive
320 (40.3)
1460 (71)
Body mass index (kg/m2)
Mean (±SD)
24 (±3.4)
21 (±3.4)
<0.001
Missing
528 (66.5)
1016 (49.5)
Total cholesterol mmol/L
Mean (±SD)
5.15 (±1.3)
4.88 (±1.4)
<0.001
Triglycerides mmol/L
Mean (±SD)
2.44 (±2)
2.40 (±2.3)
0.678
HDL-C mmol/L
Mean (±SD)
1.15 (±0.5)
1.25 (±0.4)
<0.001
*Comparison by -test for continuous variables and the test for noncontinuous variables. **Comparison by Wilcoxon rank-sum test. A: AHOD: Australian HIV Observational Database; T: TAHOD: TREAT Asia HIV Observational Database. cART: combinational antiretroviral therapy; HBV: hepatitis B coinfection; HCV: hepatitis C coinfection; IDU: Intravenous drug user; IQR: interquartile range; SD: standard deviation. ***Transgender participants were classified as males in the multivariable analyses.
